Irbesartan (SR-47436) hydrochloride 是一种 Ang II 型 1 (AT1) 受体阻滞剂 (ARB)，具有口服活性。Irbesartan hydrochloride 可放松血管，降低血压，增加血液和氧气供应到心脏。 Irbesartan hydrochloride 可用于高血压、心力衰竭和糖尿病肾病的研究。
| 生物活性 | Irbesartan (SR-47436) hydrochloride is an orally activeAng II type 1 (AT1) receptor blocker (ARB). Irbesartan hydrochloride can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan hydrochloride can be used for the research of high blood pressure, heart failure, and diabetic kidney disease[1]. |
体外研究
(In Vitro) | Irbesartan hydrochloride (20 μM, 3 h) reduces Th22 cells chemotaxis in vitro[1].
Irbesartan hydrochloride (0 μM, 20 μM, 40 μM and 60 μM) suppresses Th22 cells differentiation in vitro[1].
Irbesartan hydrochloride (20 μM) inhibits Th22 cells related proinflammatory response of TECs in vitro[1].
Cell Viability Assay[1] | Cell Line: | CD4+T cells | | Concentration: | 0, 20, 40 and 60 μM | | Incubation Time: | 48 h | | Result: | Exerted no obvious effect on viability of CD4+T cells. |
|
体内研究
(In Vivo) | Irbesartan hydrochloride (oral gavage; 50 mg/kg/d; once daily) reduces Th22 lymphocytosis and serum IL-22 level in Ang II-infused mice[1].
Irbesartan hydrochloride (oral gavage; 50 mg/kg/d; once daily) exerts obvious renoprotective effects[1].
Irbesartan hydrochloride (oral gavage; 50 mg/kg/d; once daily) relieves systemic inflammation and renal fibrosis in hypertension mice induced by Ang II[1].
Irbesartan hydrochloride (20 μM; for 3 h) can attenuate Th22 cells recruitment and IL-22 secretion, which might be through inhibiting chemotaxis in hypertensive renal injury mice[1].
| Animal Model: | C57BL/6 mice[1] | | Dosage: | 50 mg/kg | | Administration: | oral gavage; 50 mg/kg/d; once daily | | Result: | Displayed low Th22 cells and IL-22, exerted similar inhibitory effect on Th1 cell proportion and displayed decreased IL-22 level in kidney.
Prevented BP elevation markedly and decreased urinary albumin/creatinine ratio, BUN and Scr.
Repressed the expression of IL-1β, IL-6, TNF-α, α-SMA, FN and Col I and diminished the extent of fibrosis. |
| Animal Model: | C57BL/6 mice[1] | | Dosage: | 20 μM | | Administration: | 20 μM; for 3 h | | Result: | Downregulated renal CCL20, CCL22 and CCL27 concentrations. |
|
| Clinical Trial | |
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com